Business Wire

NOMAD-FOODS

9.5.2022 11:43:08 CEST | Business Wire | Press release

Share
Nomad Foods Urges Food Industry to Adopt End-to-End Carbon Impact Product Assessment to Help Tackle the Climate Emergency

Nomad Foods, Europe’s leading frozen food company, which owns brands including Birds Eye, Findus and iglo, is calling on the food industry and regulators across Europe to consider a more comprehensive, end-to-end approach to Life Cycle Assessment (LCA) studies, which includes food loss and waste impacts, to improve transparency for consumers and drive critical action to reduce carbon emissions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005425/en/

Food production is a major contributor to climate change and making better environmental choices about what we eat and how we reduce food waste is one way for businesses and consumers to lower their carbon impact. To support this action, it’s vital that food companies fully understand their products’ total emissions footprint and provide clear, accurate and complete information.

With carbon labels and previous LCA studies on food often limited in scope, Nomad Foods has recently enlisted the help of international experts in impact assessments, PRé Sustainability, to conduct a unique end-to-end LCA study for 22 of Nomad Foods’ most popular products1 .

Crucially, the study went beyond the scope of existing LCAs to include all stages of the product life cycle, incorporating new data on retailer and consumer food waste (an important element of Scope 3 emissions for food manufacturers) and primary data for all processing steps, improving the accuracy of the assessment – with the results peer reviewed by leading experts.

The study showed that retail and consumer food loss and waste – data which is not generally included in previous LCA assessments of food – plays an important part of the product life cycle and has a significant effect on a product’s overall environmental impact. In fact, retail and consumer food waste equates to an estimated 160m tonnes and 17.25m tonnes of CO2 in the EU and UK respectively2 .

This new assessment means that, for the first time ever, clear conclusions can be drawn about the carbon footprint of frozen foods products and meaningful comparisons made to their non-frozen alternatives, while accounting for all relevant and material impacts. Results for the 22 frozen products assessed under the new study showed that most had an equal or lower carbon footprint than similar products using other preservation methods.

Stéfan Descheemaeker, Chief Executive Officer, Nomad Foods, said: “Consumer demand for nutritious, high-quality, sustainable food is growing and we believe it’s vital that we find ways to provide consumers with information that helps them make informed choices and provides confidence that sustainability claims are robust and evidence-based. To support this, we encourage the food industry, retailers and regulators to adopt a wider scope for LCAs as standard, taking the whole product life cycle into account. Based on the ground-breaking work that our teams have undertaken with life cycle experts PRé Sustainability, we can see there are significant benefits to frozen food in terms of longer-term food preservation and reduced food waste.”

Ellen Meijer, Consultant, PRé Sustainability, said: “This is one of the most elaborate frozen food LCA studies ever done, covering not only a wide range of frozen food products and their alternatives, but also approaching them all in a consistent methodological manner. Combined with the large amount of primary production data included and the attention to detail at each stage, this study is one of a kind. Based on this study, we are now in the unique position to draw conclusions about the carbon footprint of frozen food products compared to their non-frozen alternatives and generalize these conclusions across the frozen food category."

About Nomad Foods
Nomad Foods (NYSE: NOMD) is Europe’s leading frozen food company. The company's portfolio of iconic brands, which includes Birds Eye , Findus , iglo , Ledo and Frikom , have been a part of consumers' meals for generations, standing for great tasting food that is convenient, high quality and nutritious. Nomad Foods is headquartered in the United Kingdom. Additional information may be found at www.nomadfoods.com .

About PRé Sustainability
For thirty years PRé Sustainability has been at the forefront of life cycle thinking and has built on its knowledge and experience in sustainability metrics and impact assessments to provide state of the art methods, consulting services and software tools. Internationally, leading organizations work with PRé to integrate sustainability into their product development procedures in order to create business growth and business value. PRé has an office in the Netherlands and a global partner network to support large international or multi-client projects. www.pre-sustainability.com .

Notes to Editors:

1 The comprehensive LCA study covered 10 keys stages. Stages 6 – 10 are the extended scope of the assessment not generally included in other studies :

  1. Ingredients : Production, including transport to factory.
  2. Processing : All activities that happen at the factory including energy, on-site waste and the treatment of it, and activities related to packaging the product. Also includes any pre-blanching or pre-freezing before it reaches the factory. The study included primary data for all material processes improving the accuracy of the assessment.
  3. Packaging : Packaging materials, including their transport to the factory.
  4. Distribution : Transport from the factory, storage at the distribution centre, transport to the retail hub and storage at the retail hub.
  5. Retail storage : Electricity and coolant use in the retail cold room and on the retail floor.
  6. Retail waste : Waste treatment of transport packaging, product losses and waste treatment of product losses, including processing, packaging and distribution of the product losses.
  7. Consumer transport : From the retailer to the consumer.
  8. Consumer storage : Electricity use for storage at the consumer.
  9. Consumer preparation : Energy use at the consumer to cook the food product, as well as any capital goods.
  10. Consumer waste : Waste treatment of primary packaging and product losses. This includes all upstream processes required to compensate for the product losses at the consumer.

2 6.9m tonnes of the UK’s annual total of 9.5m tonnes of food waste is down to the retailer and consumer, equivalent to 17.25m tonnes of CO2 (WRAP). In the EU the retail and consumer proportion of the 88m tonnes of food waste generated, equates to 160m tonnes of CO2. Calculation based on 1 kg of food waste creates 2.5 kg of CO22013; Food Wastage Footprint Impact on Natural Resources; United Nation’s Food & Agriculture Organization

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye